BETA

IPO registrations (S-1, F-1) · Registrants

Rein Therapeutics, Inc.

SEC CIK
1420565 · filings on EDGAR ↗
Former names
Aileron Therapeutics, Inc. (2024–2024); AILERON THERAPEUTICS INC (2007–2024)
Registration
Form S-1, first filed 2017-06-02, last 2026-04-28; 5 initial registrations, 2 amendments
Outcome
Final prospectus filed 2017-06-29; declared effective 2017-06-28
Industry (SIC)
Pharmaceutical Preparations 2834
Business address
12407 N. MOPAC EXPY., SUITE 250 #390, Austin, TX 78758
EIN
13-4196017
Ticker
RNTX (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
Rein Therapeutics, Inc. on the corporate pages

Offering terms

Proposed price range
$15.00–$17.00 per share (S-1/A filed 2017-06-19)
Final price
$15.00 per share, within the range (424B4 filed 2017-06-29, an initial public offering)
Shares sold
3,750,000
Gross proceeds
$56,250,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol ALRN
Lead underwriters
Merrill Lynch; Jefferies (1,237,500 shares)
Syndicate
BofA Securities; William Blair (637,500); Canaccord Genuity (375,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 20

FiledFormWhat it isName as filedEDGAR
2017-06-02S-1S-1 (registration)AILERON THERAPEUTICS INC0001193125-17-193173 ↗
2017-06-19S-1/AS-1/A (amendment)AILERON THERAPEUTICS INC0001193125-17-206488 ↗
2017-06-28EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-17-001682 ↗
2017-06-29424B4424B4 (final prospectus)AILERON THERAPEUTICS INC0001193125-17-217947 ↗
2019-05-01S-1S-1 (registration)AILERON THERAPEUTICS INC0001193125-19-130164 ↗
2019-05-13S-1/AS-1/A (amendment)AILERON THERAPEUTICS INC0001193125-19-145446 ↗
2019-05-14EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-19-001121 ↗
2019-07-15EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-19-001591 ↗
2019-07-16EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-19-001610 ↗
2020-08-21EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-20-002222 ↗
2020-10-05S-1S-1 (registration)AILERON THERAPEUTICS INC0001193125-20-263968 ↗
2020-10-15EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-20-002868 ↗
2021-02-09EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-21-000535 ↗
2022-06-16EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-22-001808 ↗
2024-02-05EFFECTEFFECT (declared effective)AILERON THERAPEUTICS INC9999999995-24-000319 ↗
2025-05-22EFFECTEFFECT (declared effective)Rein Therapeutics, Inc.9999999995-25-001721 ↗
2025-09-03S-1S-1 (registration)Rein Therapeutics, Inc.0001193125-25-195041 ↗
2025-09-05EFFECTEFFECT (declared effective)Rein Therapeutics, Inc.9999999995-25-002855 ↗
2026-04-28S-1S-1 (registration)Rein Therapeutics, Inc.0001193125-26-187803 ↗
2026-04-30EFFECTEFFECT (declared effective)Rein Therapeutics, Inc.9999999995-26-001417 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2017-06-19S-1/Aregistration statement$15.00–$17.003,750,000-Nasdaq ALRN5primary document; range, shares headline, cover names 4document ↗
2017-06-29424B4final prospectus$15.003,750,000$56,250,000Nasdaq ALRN5primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Aivado ManuelDirector; Director,Officer; OfficerPresident and CEO; See Remarks122017–2025
AJU IB Investment Co., Ltd.TenPercentOwner22017
Ambros Reinhard J.Director142017–2025
Annis AllenOfficer; TenPercentOwnerSee Remarks; SVP, Research72017–2022
Apple Tree Partners II - Annex, L.P.TenPercentOwner32017–2018
APPLE TREE PARTNERS II LPTenPercentOwner102017–2018
Blume Frederick R.TenPercentOwner22017
CVF, LLCTenPercentOwner22017
Dougherty DonaldOfficerSVP & Chief Financial Officer62017–2019
Enriquez JuanTenPercentOwner22017
EXCEL MEDICAL FUND LPTenPercentOwner22017
Excel Medical Ventures, LLCTenPercentOwner22017
Gallagher Brian M. Jr.Director32017
GLAXOSMITHKLINE PLCTenPercentOwner12017
Gullans Steven R. Ph.D.TenPercentOwner22017
Hall Steven EdwardOther; TenPercentOwner22017
Kapnick ScottDirector; Director,TenPercentOwner42017–2018
KCK LTD.TenPercentOwner22017
Lilly Ventures Fund I LLCOther; TenPercentOwner22017
LV Management Group, LLCOther; TenPercentOwner22017
MCARTHUR JOHN HDirector42017–2019
Morrison Jodie PopeDirector72017–2022
Nelson KiraOfficerSee Remarks22017
NOVARTIS AGTenPercentOwner162017–2019
Novartis Bioventures LtdTenPercentOwner162017–2019
Platt Jon B.TenPercentOwner22017
ROCHE FINANCE LTDTenPercentOwner32017
ROCHE HOLDING LTDTenPercentOwner32017
Satter Muneer ADirector,Officer; Director,TenPercentOwnerOther; TenPercentOwner; TenPercentOwnerOtherSee Remarks52017–2021
Shanafelt ArmenDirector; Director,TenPercentOwner42017–2018
Sigma Emerging Markets Ltd.TenPercentOwner22017
Torres S. EdwardOther; TenPercentOwner22017person page Fuzzy
Winder Caleb MaxfieldDirector32017–2018
Yanchik Joseph A., IIIDirector,Officer; Director,Officer,TenPercentOwnerSee Remarks22017
Bailey Jeffrey AllenDirector92018–2022
LONGENECKER JOHN P PHDOfficerPresident and CEO32018
Vukovic VojoOfficerChief Medical Officer; SVP, Chief Medical Officer82018–2022
Gregory KathrynOfficerSVP, Chief Business Officer52019–2020
Sigal Nolan HowardDirector62019–2022
Wanstall RickOfficerSee Remarks; VP, Finance and Operations72019–2022
MCKEE WILLIAMDirector52019–2022
VON RICKENBACH JOSEF HDirector162019–2026
Drexler Susan L.OfficerSee Remarks12022
Fairey WilliamDirector52023–2025
Musso Alan ADirector52023–2025
WINDSOR JAMES BRIANDirector,Officer; OfficerPresident and CEO; President and COO; See Remarks72023–2026
Garner CharlesOfficerSenior Vice President, Finance12024
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT COTenPercentOwner62024
Cunningham Timothy M.OfficerSee Remarks12024
Cocke Travis W.TenPercentOwner32025
Voss Advisors GP, LLCTenPercentOwner32025
Voss Capital, LPTenPercentOwner32025
Voss Value Master Fund, LPTenPercentOwner32025
Voss Value-Oriented Special Situations Fund, LPTenPercentOwner32025

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2023-11-16AILERON THERAPEUTICS INCBiotechnology$18,254,247$18,254,247151
2017-01-06AILERON THERAPEUTICS INCBiotechnology$40,000,000$30,112,894111
2014-10-29AILERON THERAPEUTICS INCBiotechnology$32,999,999$19,799,999131

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationREIN THERAPEUTICS, INC.TXState business registriesname and state
Form D issuerAILERON THERAPEUTICS INCMAForm D private offeringsCIK (EXACT)
Patent assigneeRein Therapeutics, Inc.TXPatents (USPTO)name and state
SEC filerRein Therapeutics, Inc.SEC filers (EDGAR)CIK (EXACT)
Form 5500 plan sponsorAILERON THERAPEUTICS, INC.EIN (EXACT)
Person pageS Edward TorresPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Other)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, TX first:

More with this interest.

In other datasets, the same topic (Health) in TX:

Interests: Pharmaceutical Preparations · Health